TiNiSi-type MnCoSi-based alloys show large magnetostriction during the magnetic-field-induced metamagnetic transition. However, the high critical field required to drive the transition directly hinders their potential applications. In this work, we systematically investigate the tricritical behavior and magnetostrictive effect in substituted MnCoSi alloys. Replacing Si with Sb or In, Co with Fe or Cu, and Mn with Co, which can simultaneously reduce the critical field and the temperature of tricritical point, are explored. Among the substituted MnCoSi alloys, Mn_0.983Co_1.017Si displays a temperature of a tricritical point of 250 K and a room-temperature critical field of 0.60 T, which is the lowest up to now. Profited from these optimizations, a large reversible magnetostrictive effect under low field is successfully realized at room temperature. In a field of 1 T, the magnetostriction of Mn_0.983Co_1.017Si alloy is close to 1000 ppm. Besides, a strong relation between critical field and valence electron concentration is revealed in the transition-metal-substituted MnCoSi alloys. Our work greatly enhances the low-field magnetostrictive performance of MnCoSi-based alloys and make them be of interest in potential applications.

Progress in high-throughput metabolic profiling provides unprecedented opportunities to obtain insights into the effects of drugs on human metabolism. The Biobanking BioMolecular Research Infrastructure of the Netherlands has constructed an atlas of drug–metabolite associations for 87 commonly prescribed drugs and 150 clinically relevant plasma-based metabolites assessed by proton nuclear magnetic resonance. The atlas includes a meta-analysis of ten cohorts (18,873 persons) and uncovers 1,071 drug–metabolite associations after evaluation of confounders including co-treatment. We show that the effect estimates of statins on metabolites from the cross-sectional study are comparable to those from intervention and genetic observational studies. Further data integration links proton pump inhibitors to circulating metabolites, liver function, hepatic steatosis and the gut microbiome. Our atlas provides a tool for targeted experimental pharmaceutical research and clinical trials to improve drug efficacy, safety and repurposing. We provide a web-based resource for visualization of the atlas (http://bbmri.researchlumc.nl/atlas/).